Skip to main content
. 2024 Feb 20;14(1):22–30. doi: 10.62347/WCZR2136

Table 3.

Characteristics and statistical results of the patients grouped according to their chemotherapy history

Variables Groups P value**

A: No prior chemotherapy* B: During chemotherapy* C: Previous chemotherapy*
Vertebral-SUV 1.69 (0.79-3.07) 1.49 (0.69-2.53) 1.40 (0.56-2.11) 0.04 (A vs B)
< 0.01 (A vs C)
0.74 (B vs C)
Femoral-SUV 0.68 (0.21-1.85) 0.70 (0.24-1.13) 0.63 (0.24-1.63) 0.76
BM-CT number -31.0 (-85.3-60.5) -22.7 (-81.5-13.6) -33.2 (-78.6-25.1) 0.35
Age (years) 66 (22-87) 69 (44-79) 65.8 (24-86) 0.41
Male/female 74/75 11/12 20/35 0.24***
BS (mg/dL) 103.1 (76-149) 102.0 (45-147) 103.4 (78-139) 0.92
BW (kg) 59.3 (35.4-114.1) 54.1 (40.8-85.5) 56.5 (30.8-83.5) 0.18
WBC count (× 103/μL) 6.20 (3.20-1.72) 4.47 (1.80-11.10) 4.78 (1.80-1.89) < 0.01 (A vs B)
0.04 (A vs C)
0.74 (B vs C)
Hgb (mg/dL) 13.2 (8.0-17.0) 10.9 (7.8-15.0) 12.4 (7.6-15.4) < 0.01 (A vs B)
< 0.01 (A vs C)
0.03 (B vs C)
Plt count (× 103/μL) 255.7 (13.6-572.0) 221.0 (58.0-444.0) 214.3 (28.0-364.0) < 0.01 (A vs C)
0.01 (A vs B)
1.00 (B vs C)
CRP (mg/dL) 0.23 (0.01-12.9) 0.15 (0.01-8.4) 0.18 (0.02-4.68) 0.44

Values are presented as median (range). SUV, standardized uptake value; BM, bone marrow; CT, computed tomography; BS, blood sugar; BW, body weight; WBC, white blood cell; Hgb, hemoglobin; Plt, platelet; CRP, C-reactive protein.

*

No prior chemotherapy: patients who had never received anticancer chemotherapy; during chemotherapy: patients who had received anticancer chemotherapy within 30 days previously; previous chemotherapy: patients who had received anticancer chemotherapy more than 30 days previously.

**

Results of the Kruskal-Wallis H test and Mann-Whitney U test with Bonferroni correction.

***

Results of the chi-square test.